TheraPPI Bioscience SAS (“TheraPPI”), a preclinical biotechnology company focused on developing small molecules that modify protein interactions, announced today the first closing of its Pre-Seed financing. The Geneva-based company aims to advance its lead oncology program targeting a novel protein interaction.

TheraPPI生物科学公司（“TheraPPI”），一家专注于开发修饰蛋白质相互作用小分子的临床前生物技术公司，今天宣布了其预种子轮融资的首次关闭。这家位于日内瓦的公司旨在推进其针对一种新型蛋白质相互作用的领先肿瘤学项目。

All investors have substantial experience in the biotech sector..

所有投资者在生物技术领域都有丰富的经验。

TheraPPI

TheraPPI

will use the proceeds today announced to advance the development of its lead program targeting ERK/MyD88, a novel protein interaction in the Ras-MAPK pathway to tackle cancer drug resistance and to offer more effective and safer therapies to patients with advanced cancers.

将利用今天宣布的收益来推进其针对ERK/MyD88的主导项目开发，这是一种在Ras-MAPK通路中的新型蛋白相互作用，旨在解决癌症药物耐药性问题，并为晚期癌症患者提供更有效且更安全的治疗方案。

TheraPPI also announced the inception of TheraPPI Bioscience SA (Geneva, Switzerland) and the nomination of a Board of Directors of this new company. Patricia Delaite, MD, a clinical oncologist and executive in biotech companies, joins the company’s Board as Chairwoman. John Tchelingerian, PhD, a serial entrepreneur and private investor in the biotech sector, and Barthélemy Helg, LL.

TheraPPI 还宣布了 TheraPPI Bioscience SA（瑞士日内瓦）的成立以及新公司董事会的任命。临床肿瘤学家及生物技术公司高管 Patricia Delaite 医学博士加入公司董事会并担任主席。生物技术领域的连续创业者和私人投资者 John Tchelingerian 博士，以及 Barthélemy Helg。

M. & MBA, an executive in the biotech and food tech sectors, join the company’s Board as independent Directors. Luc Otten, MD, PhD, founder CEO, and Toufic Renno, PhD, founder CSO of TheraPPI, are also Board Directors..

医学博士和工商管理硕士，生物技术和食品技术领域的高管，作为独立董事加入公司董事会。路克·奥滕，医学博士及哲学博士，TheraPPI 的创始人兼首席执行官，以及托菲克·雷诺，哲学博士，TheraPPI 的创始人兼首席科学官，也是董事会成员。

“TheraPPI is developing a first-in-class drug for bringing efficacious therapy to patients with cancer who can’t any longer benefit from modern targeted therapies or immunotherapies. TheraPPI lead program tackles a real unmet medical need by fighting cancer drug resistance, a major cause of death. I am deeply honoured to support TheraPPI on this exciting journey,” said Patricia Delaite.

“TheraPPI 正在开发一种首创新药，为那些无法再从现代靶向治疗或免疫疗法中受益的癌症患者提供有效的治疗。TheraPPI 的主导项目通过对抗癌症耐药性这一导致死亡的主要原因，解决了真正的未满足医疗需求。我深感荣幸能够在这令人兴奋的旅程中支持 TheraPPI，”Patricia Delaite 表示。

“Thanks to the support of our new investors, our Board of Directors, and this open Pre-Seed financing round, we are moving forward by expediting TheraPPI’s lead program and preparing additional developments. The combination of long experience in both academia and industry from the team with strong corporate governance provides a solid foundation for future TheraPPI successes,” added Luc Otten..

“感谢我们的新投资者、董事会以及这次公开的前种子轮融资，我们正在加快推进TheraPPI的主导项目，并准备进一步的发展。团队在学术界和工业界拥有丰富经验，并结合强有力的企业管理，为TheraPPI未来的成功奠定了坚实的基础，”卢克·奥滕补充道。

TheraPPI is a preclinical-stage biotech company developing protein interaction-modifying drugs to provide patients with better treatments in oncology, rare diseases, and inflammatory conditions. TheraPPI consists of TheraPPI Bioscience SAS based in Lyon, France and TheraPPI Bioscience SA based in Geneva, Switzerland..

TheraPPI是一家处于临床前阶段的生物技术公司，致力于开发蛋白质相互作用修饰药物，为肿瘤学、罕见病和炎症性疾病患者提供更好的治疗。TheraPPI由位于法国里昂的TheraPPI生物科学公司（TheraPPI Bioscience SAS）和位于瑞士日内瓦的TheraPPI生物科学公司（TheraPPI Bioscience SA）组成。

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送